Skip to main content
SpringerLink
Log in

Treatment of Psychotic Disorders

  • Chapter
  • First Online:
Pharmacotherapy of Depression

Abstract

Depression is common among patients with schizophrenia and is associated with a wide range of poor outcomes, including psychotic relapse and suicide. Although some dysphoria may be an adverse medication effect from conventional neuroleptics and some depressive reactions may follow resolution of a psychotic episode or represent demoralization, often depression appears to be a chronic, comorbid condition that can be present throughout the entire course of the illness, from prodromal schizophrenia to aging schizophrenia patients.

This is a preview of subscription content, log in via an institution to check access.

Access this chapter

Log in via an institution
Chapter
USD 29.95
Price excludes VAT (USA)
  • Available as PDF
  • Read on any device
  • Instant download
  • Own it forever
eBook
USD 89.00
Price excludes VAT (USA)
  • Available as EPUB and PDF
  • Read on any device
  • Instant download
  • Own it forever
Softcover Book
USD 119.99
Price excludes VAT (USA)
  • Compact, lightweight edition
  • Dispatched in 3 to 5 business days
  • Free shipping worldwide - see info
Hardcover Book
USD 169.99
Price excludes VAT (USA)
  • Durable hardcover edition
  • Dispatched in 3 to 5 business days
  • Free shipping worldwide - see info

Tax calculation will be finalised at checkout

Purchases are for personal use only

Institutional subscriptions

References

  1. Lindenmayer J-P, Grochowski S, Hyman RB. Five factor model of schizophrenia: replication across samples. Schizophr Res. 1995;14:229–34.

    Article  PubMed  CAS  Google Scholar 

  2. Marder SR, Davis JM, Chouinard G. The effects of risperidone on the five dimensions of schizophrenia derived by factor analysis: combined results of the North American trials. J Clin Psychiatry. 1997;58:538–46.

    Article  PubMed  CAS  Google Scholar 

  3. Bartels SJ, Drake RE. Depressive symptoms in schizophrenia: comprehensive differential diagnosis. Compr Psychiatry. 1988;29:467–83.

    Article  PubMed  CAS  Google Scholar 

  4. DeLisi LE. Depression in Schizophrenia. Washington: American Psychiatric Press; 1990.

    Google Scholar 

  5. Siris SG. Depression in schizophrenia: perspective in the era of “atypical” antipsychotic agents. Am J Psychiatry. 2000;157:1379–89.

    Article  PubMed  CAS  Google Scholar 

  6. Zisook S, McAdams LA, Kuck J, Harris MJ, Bailey A, Patterson TL, et al. Depressive symptoms in schizophrenia. Am J Psychiatry. 1999;156:1736–43.

    PubMed  CAS  Google Scholar 

  7. Wassink TH, Flaum M, Nopoulos P, Andreasen NC. Prevalence of depressive symptoms early in the course of schizophrenia. Am J Psychiatry. 1999;156:315–6.

    PubMed  CAS  Google Scholar 

  8. Sands JR, Harrow M. Depression during the longitudinal course of schizophrenia. Schizophr Bull. 1999;25:157–71.

    Article  PubMed  CAS  Google Scholar 

  9. Rosen JL, Miller TJ, D’Andrea JT, McGlashan TH, Woods SW. Comorbid diagnoses in patients meeting criteria for the schizophrenia prodrome. Schizophr Res. 2006;85:124–31.

    Article  PubMed  Google Scholar 

  10. Koreen AR, Siris SG, Chakos M, Alvir J, Mayerhoff D, Lieberman J. Depression in first-episode schizophrenia. Am J Psychiatry. 1993;150:1643–8.

    PubMed  CAS  Google Scholar 

  11. Hafner H, Maurer K, Trendler G, an der Heiden W, Schmidt M, Konnecke R. Schizophrenia and depression: challenging the paradigm of two separate diseases – a controlled study of schizophrenia, depression and healthy controls. Schiz Res. 2005;77:11–24.

    Google Scholar 

  12. an der Heiden W, Konnecke R, Maurer K, Ropeter D, Hafner H. Depression in the long-term course of schizophrenia. Eur Arch Psychiatry Clin Neurosci. 2005;255:174–84.

    Google Scholar 

  13. Jin H, Zisook S, Palmer BW, Patterson TL, Heaton RK, Jeste DV. Association of depressive symptoms with worse functioning in schizophrenia: a study in older outpatients. J Clin Psychiatry. 2001;62:797–803.

    Article  PubMed  CAS  Google Scholar 

  14. Hogarty GE, McEvoy JP, Ulrich RF, DiBarry AL, Bartone P, Cooley S, et al. Pharmacotherapy of impaired affect in recovering schizophrenic patients. Arch Gen Psychiatry. 1995;52:29–41.

    Article  PubMed  CAS  Google Scholar 

  15. Newcomer JW, Faustman WO, Yeh W, Csernansky JG. Distinguishing depression and negative symptoms in unmedicated patients with schizophrenia. Psychiatry Res. 1989;31:243–50.

    Article  Google Scholar 

  16. Addington D, Addington T, Maticka-Tyndale E. Reliability and validity of a depression rating scale for schizophrenics. Schizophr Res. 1992;6:201–8.

    Article  PubMed  CAS  Google Scholar 

  17. Norman RMG, Malla AK. Dysphoric mood and symptomatology in schizophrenia. Psychol Med. 1991;21:897–903.

    Article  PubMed  CAS  Google Scholar 

  18. Sax KW, Strakowski SM, Keck PEJ, Upadhyaya VH, West SA, McElroy SL. Relationships among negative, positive, and depressive symptoms in schizophrenia and psychotic depression. Br J Psychiatry. 1996;168:68–71.

    Article  PubMed  CAS  Google Scholar 

  19. Vaillant GE. Prospective prediction of schizophrenic remission. Arch Gen Psychiatry. 1964;11:509–18.

    Article  PubMed  CAS  Google Scholar 

  20. Conley RR, Ascher-Svanum H, Zhu B, Faries DE, Kinon BJ. The burden of depressive symptoms in the long-term treatment of patients with schizophrenia. Schizophr Res. 2007;90:186–97.

    Article  PubMed  Google Scholar 

  21. Tollefson GD, Andersen SW. Should we consider mood disturbance in schizophenia as an important determinant of quality of life? J Clin Psychiatry. 1999;60 (suppl 5):23–9.

    PubMed  CAS  Google Scholar 

  22. Tollefson GD, Andersen SW, Tran PV. The course of depressive symptoms in predicting relapse in schizophrenia: a double-blind, randomized comparison of olanzapine and risperidone. Biol Psychiatry. 1999;46:365–73.

    Article  PubMed  CAS  Google Scholar 

  23. Johnson DAW. The significance of depression in the prediction of relapse in chronic schizophrenia. Br J Psychiatry. 1988;152:320–3.

    Article  PubMed  CAS  Google Scholar 

  24. Mandel MR, Severe JB, Schooler NR, Gelenberg AJ, Mieske M. Development and prediction of postpsychotic depression in neuroleptic-treated schizophrenics. Arch Gen Psychiatry. 1982;39:197–203.

    Article  PubMed  CAS  Google Scholar 

  25. Roy A, Thompson R, Kennedy S. Depression in chronic schizophrenia. Br J Psychiatry. 1983;142:465–70.

    Article  PubMed  CAS  Google Scholar 

  26. Caldwell CB, Gottesman II. Schizophrenics kill themselves too: a review of risk factors for suicide. Schizophr Bull. 1990;16:571–89.

    Article  PubMed  CAS  Google Scholar 

  27. Palmer BA, Pankratz VS, Bostwick JM. The lifetime risk of suicide in schizophrenia: a reexamination. Arch Gen Psychiatry. 2005;62:247–53.

    Article  PubMed  Google Scholar 

  28. Saeedi H, Addington J, Addington D. The association of insight with psychotic symptoms, depression, and cognition in early psychosis: a 3-year follow-up. Schizophr Res. 2007;89:123–8.

    Article  PubMed  Google Scholar 

  29. Crumlish N, Whitty P, Kamali M, Clarke M, Browne S, McTigue O, et al. Early insight predicts depression and attempted suicide after 4 years in first-episode schizophrenia and schizophreniform disorder. Acta Psychiatr Scand. 2005;112:449–55.

    Article  PubMed  CAS  Google Scholar 

  30. Voruganti LP, Awad AG. Is neuroleptic dysphoria a variant of drug-induced extrapyramidal side effects? Can J Psychiatry. 2004;49:285–9.

    PubMed  Google Scholar 

  31. Van Putten T, May PRA. ‘Akinetic depression’ in schizophrenia. Arch Gen Psychiatry. 1978;35:1101–7.

    Article  PubMed  Google Scholar 

  32. Van Putten T, May PRA. Subjective response as a predictor of outcome in pharmacotherapy. Arch Gen Psychiatry. 1978;35:477–80.

    Article  PubMed  Google Scholar 

  33. Tollefson GD, Sanger TM, Lu Y, Thieme ME. Depressive signs and symptoms in schizophrenia: A prospective blinded trial of olanzapine and haloperidol. Arch Gen Psychiatry. 1998;55:250–8.

    Article  PubMed  CAS  Google Scholar 

  34. Regier DA, Farmer ME, Rae DS, Locke BZ, Keith SJ, Judd LL, et al. Comorbidity of mental disorders with alcohol and other drug abuse. Results from the Epidemiological Catchment Area (ECA) Study. JAMA. 1990;264:2511–8.

    Article  PubMed  CAS  Google Scholar 

  35. Wilkins JN, Shaner AL, Patterson CM, Setoda D, Gorelick D. Discrepancies between patient report, clinical assessment, and urine analysis in psychiatric patients during inpatient admission. Psychopharmacol Bull. 1991;27:149–54.

    PubMed  CAS  Google Scholar 

  36. Shaner A, Eckman TA, Roberts LJ, Wilkins JN, Tucker DE, Tsuang JW, et al. Disability income, cocaine use, and repeated hospitalization among schizophrenic cocaine abusers.N Engl J Med. 1995;333:777–83.

    Article  PubMed  CAS  Google Scholar 

  37. Serper MR, Alpert M, Richardson NA, Dickson S, Allen MH, Werner A. Clinical effects of recent cocaine use on patients with acute schizophrenia. Am J Psychiatry. 1995;152:1464–9.

    PubMed  CAS  Google Scholar 

  38. Vollmer-Larsen A, Jacobsen TB, Hemmingsen R, Parnas J. Schizoaffective disorder – the reliability of its clinical diagnostic use. Acta Psychiatr Scand. 2006;113:402–7.

    Article  PubMed  CAS  Google Scholar 

  39. Hausmann A, Fleischhacker WW. Differential diagnosis of depressed mood in patients with schizophrenia: a diagnostic algorithm based on a review. Acta Psychiatr Scand. 2002;106:83–96.

    Article  PubMed  CAS  Google Scholar 

  40. Siris SG, Rifkin A, Reardon GT, Doddi SR, Strahan A, Hall KS. Stability of the postpsychotic depression syndrome. J Clin Psychiatry. 1986;47:86–8.

    PubMed  CAS  Google Scholar 

  41. Knights A, Hirsch SR. “Revealed” depression and drug treatment for schizophrenia. Arch Gen Psychiatry. 1981;38:806–11.

    Article  PubMed  CAS  Google Scholar 

  42. Green MF, Nuechterlein KH, Ventura J, Mintz J. The temporal relationship between depressive and psychotic symptoms in recent-onset schizophrenia. Am J Psychiatry. 1990;147:179–82.

    PubMed  CAS  Google Scholar 

  43. Bressan RA, Chaves AC, Pilowsky LS, Shirakawa I, Mari JJ. Depressive episodes in stable schizophrenia: critical evaluation of the DSM-IV and ICD-10 diagnostic criteria. Psychiatry Res. 2003;117:47–56.

    Article  PubMed  Google Scholar 

  44. Herz M. Prodromal symptoms and prevention of relapse in schizophrenia. J Clin Psychiatry. 1985;46:22–5.

    PubMed  CAS  Google Scholar 

  45. Kane J, Honigfeld G, Singer J, Meltzer H. Clozapine for the treatment-resistant schizophrenic. A double-blind comparison with chlorpromazine. Arch Gen Psychiatry. 1988;45:789–96.

    Article  PubMed  CAS  Google Scholar 

  46. Davis JM, Chen N. The effects of olanzapine on the 5 dimensions of schizophrenia derived by factor analysis: combined results of the North American and international trials. J Clin Psychiatry. 2001;62:757–71.

    Article  PubMed  CAS  Google Scholar 

  47. Keck Jr. P, Buffenstein A, Ferguson J, Feighner J, Jaffe W, Harrigan EP, et al. Ziprasidone 40 and 120 mg/day in the acute exacerbation of schizophrenia and schizoaffective disorder: a 4-week placebo-controlled trial. Psychopharmacology. 1998;140:173–84.

    Article  PubMed  CAS  Google Scholar 

  48. Moeller HJ. Occurrence and treatment of depressive comborbidity/cosyndromality in schizophrenic psychoses: conceptual and treatment issues. World J Biol Psychiatry. 2005;6:247–63.

    Article  Google Scholar 

  49. Tran P, Hamilton S, Kuntz A, Potvin J, Andersen S, Beasley C, et al. Double-blind comparison of olanzapine versus risperidone in the treatment of schizophrenia and other psychotic disorders. J Clin Psychopharmacology. 1997;17:407–18.

    Article  CAS  Google Scholar 

  50. Conley RR, Mahmoud R. A randomized double-blind study of risperidone and olanzapine in the treatment of schizophrenia or schizoaffective disorder. Am J Psychiatry. 2001;158:765–74.

    Article  PubMed  CAS  Google Scholar 

  51. Shelton RC, Tollefson GD, Tohen M, Stahl S, Gannon KS, Jacobs TG, et al. A novel augmentation strategy for treating resistant major depression. Am J Psychiatry. 2001;158:131–4.

    Article  PubMed  CAS  Google Scholar 

  52. Brandon S, Cowley P, McDonald C. Leicester ECT trial: results in schizophrenia. Br J Psychiatry. 1985;146:177–83.

    Article  PubMed  CAS  Google Scholar 

  53. Fink M, Sackeim HA. Convulsive therapy in schizophrenia? Schizophr Bull. 1996;22:27–39.

    Article  PubMed  CAS  Google Scholar 

  54. Taylor P, Fleminger JJ. ECT for schizophrenia. Lancet. 1980;1:1380–3.

    Article  PubMed  CAS  Google Scholar 

  55. Kramer M, Vogel W, DiJohnson C, Dewey D, Sheves P, Cavicchia S, et al. Antidepressants in ‘depressed’ schizophrenic inpatients: a controlled trial. Arch Gen Psychiatry. 1989;46:922–8.

    Article  PubMed  CAS  Google Scholar 

  56. Plasky P. Antidepressant usage in schizophrenia. Schizophr Bull. 1991;17:649–57.

    Article  PubMed  CAS  Google Scholar 

  57. Singh AN, Saxena B, Nelson HL. A controlled clinical study of trazodone in chronic schizophrenic patients with pronounced depressive symptomatology. Curr Ther Res. 1978;23:485–501.

    Google Scholar 

  58. Siris SG, Morgan V, Fagerstrom R, Rifkin A, Cooper TB. Adjunctive imipramine in the treatment of postpsychotic depression. Arch Gen Psychiatry. 1987;44:533–9.

    Article  PubMed  CAS  Google Scholar 

  59. Siris SG, Bermanzohn PC, Gonzalez A, Mason SE, White CV, Shuwall MA. The use of antidepressants for negative symptoms in a subset of schizophrenic patients. Psychopharmacol Bull. 1991;27:331–5.

    PubMed  CAS  Google Scholar 

  60. Siris S, Bermazohn P, Mason S, Shuwall M. Maintenance imipramine therapy for secondary depression in schizophrenia. Arch Gen Psychiatry. 1994;51:109–15.

    Article  PubMed  CAS  Google Scholar 

  61. Prusoff VA, Williams DH, Weissman MM, Astrachan BM. Treatment of secondary depression in schizophrenia. Arch Gen Psychiatry. 1979;36:569–75.

    Article  PubMed  CAS  Google Scholar 

  62. Waehrens J, Gerlach J. Antidepressant drugs in anergic schizophrenia. Acta Psychiatr Scand. 1980;61:438–44.

    Article  PubMed  CAS  Google Scholar 

  63. Johnson D. Studies of depressive symptoms in schizophrenia. Br J Psychiatry. 1981;139:89–101.

    Article  PubMed  CAS  Google Scholar 

  64. Freudenreich O, Goff DC. Antipsychotics. In: Ciraulo DA, Shader RI, Greenblatt D, Creelman W, editors. Drug interactions in psychiatry. 3rd ed. Philadelphia, PA: Lippincott Williams & Wilkins. 2005.

    Google Scholar 

  65. Rummel C, Kissling W, Leucht S. Antidepressants as add-on treatment to antipsychotics for people with schizophrenia and pronounced negative symptoms: a systematic review of randomized trials. Schizophr Res. 2005;80:85–97.

    Article  PubMed  Google Scholar 

  66. Mulholland C, Lynch G, Cooper SI. A double-blind, placebo-controlled trial of sertraline for depressive symptoms in stable chronic schizophrenia. Biol Psychiatry. 1997;42:188S.

    Article  Google Scholar 

  67. Addington D, Addington J, Patten S, Remington G, Moamai J, Labelle A, et al. Double-blind, placebo-controlled comparison of the efficacy of sertraline as treatment for a major depressive episode in patients with remitted schizophrenia. J Clin Psychopharmacol. 2002;22:20–5.

    Article  PubMed  CAS  Google Scholar 

  68. Kirli S, Caliskan M. A comparative study of sertraline versus imipramine in postpsychotic depressive disorder of schizophrenia. Schizophr Res. 1998;33:103–11.

    Article  PubMed  CAS  Google Scholar 

  69. Evins A, Goff D. Adjunctive antidepressant drug therapies in the treatment of negative symptoms of schizophrenia. CNS Drugs. 1996;6:130–47.

    Article  CAS  Google Scholar 

  70. Siris SG, Cooper TB, Rifkin AE, Brenner R, Lieberman JA. Plasma imipramine concentrations in patients receiving concomitant fluphenazine decanoate. Am J Psychiatry. 1982;139:104–6.

    PubMed  CAS  Google Scholar 

  71. Goff D, Midha K, Sarid-Segal O, Hubbard J, Amico E. A placebo-controlled trial of fluoxetine added to neuroleptic in patients with schizophrenia. Psychopharmacology. 1995;117:417–23.

    Article  PubMed  CAS  Google Scholar 

  72. Pierson K, Addington D, Addington J, Patten S. Serum monitoring of antipsychotic drug levels during concomitant administration of sertraline and antipsychotic medication. CanJ Psychiatry. 2006;51:715–8.

    PubMed  Google Scholar 

  73. Spina E, D’Arrigo C, Migliardi G, Morgante L, Zoccali R, Ancione M, et al. Plasma risperidone concentrations during combined treatment with sertraline. Ther Drug Monit. 2004;26:386–90.

    Article  PubMed  CAS  Google Scholar 

  74. Wetzel H, Anghelescu I, Szegedi A, Wiesner J, Weigmann H, Hartter S, et al. Pharmacokinetic interactions of clozapine with selective serotonin reuptake inhibitors: differential effects of fluvoxamine and paroxetine in a prospective study. J Clin Psychopharmacol. 1998;18:2–9.

    Article  PubMed  CAS  Google Scholar 

  75. Spina E, Avenoso A, Salemi M, Facciola G, Scordo MG, Ancione M. Plasma concentrations of clozapine and its major metabolites during combined treatment with paroxetine or sertraline. Pharmacopsychiatry. 2000;33:213–7.

    Article  PubMed  CAS  Google Scholar 

  76. Buchanan RW, Kirkpatrick B, Bryant N, Ball P, Breier A. Fluoxetine augmentation of clozapine treatment in patients with schizophrenia. Am J Psychiatry. 1996;153:1625–7.

    PubMed  CAS  Google Scholar 

  77. Gossen D, De Suray J, Vandenhende F, Onkelinx C, Gangji D. Influence of fluoxetine on olanzapine pharmacokinetics. AAPS Pharmsci. 2002;4:E11.

    Article  PubMed  Google Scholar 

  78. Whitehead C, Moss S, Cardno A, Lewis G. Antidepressants for the treatment of depression in people with schizophrenia: a systematic review. Psychol Med. 2003;330:589–99.

    Article  PubMed  CAS  Google Scholar 

Download references

Author information

Authors and Affiliations

  1. Schizophrenia Program, Massachusetts General Hospital, Freedom Trail Clinic, 25 Staniford Street, Boston, MA, 02114, USA

    Oliver Freudenreich

  2. Harvard Medical School, Boston, MA, USA

    Oliver Freudenreich

Authors
  1. Oliver Freudenreich
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Donald C. Goff
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to Oliver Freudenreich .

Editor information

Editors and Affiliations

  1. School of Medicine, Div. Psychiatry, Boston University, Harrison Ave. 720, Boston, 02118, Massachusetts, USA

    Domenic A. Ciraulo

  2. School of Medicine, Dept. Pharmacology &, Tufts University, Harrison Ave. 136, Boston, 02111, Massachusetts, USA

    Richard Irwin Shader

Rights and permissions

Reprints and permissions

Copyright information

© 2011 Springer Science+Business Media, LLC

About this chapter

Cite this chapter

Freudenreich, O., Goff, D.C. (2011). Treatment of Psychotic Disorders. In: Ciraulo, D., Shader, R. (eds) Pharmacotherapy of Depression. Humana Press, Totowa, NJ. https://doi.org/10.1007/978-1-60327-435-7_4

Download citation

  • DOI: https://doi.org/10.1007/978-1-60327-435-7_4

  • Published:

  • Publisher Name: Humana Press, Totowa, NJ

  • Print ISBN: 978-1-60327-434-0

  • Online ISBN: 978-1-60327-435-7

  • eBook Packages: MedicineMedicine (R0)

Publish with us

Policies and ethics

Search

Navigation